BC Week In Review | Jan 12, 2018
Clinical News

IDMC recommends discontinuing Phase III of Axsome's AXS-02 for complex regional pain syndrome

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended discontinuing for futility the Phase III CREATE-1 trial of once-weekly oral AXS-02 (disodium zoledronate tetrahydrate) for six weeks to treat pain associated with complex regional pain syndrome...
BC Week In Review | Jan 12, 2018
Clinical News

IDMC recommends continuation of Phase III knee OA trial for Axsome's AXS-02

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended continuing the Phase III COAST-1 trial of AXS-02 (disodium zoledronate tetrahydrate) to treat pain caused by osteoarthritis (OA) of the knee associated with bone marrow lesions following...
BC Week In Review | Dec 8, 2017
Financial News

Axsome raises $9.5M in direct offering

CNS company Axsome Therapeutics Inc. (NASDAQ:AXSM) raised $9.5 million through the sale of 1.8 million units at $5.33 in a registered direct offering led by HC Wainwright. Each unit represents one share of common stock...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BC Extra | Nov 20, 2015
Financial News

Axsome dips after $51M IPO

Axsome Therapeutics Inc. (NASDAQ:AXSM) slipped $0.26 to $8.74 on Thursday after raising $51 million through the sale of 5.7 million shares at $9 in an IPO underwritten by Ladenburg Thalmann, Cantor Fitzgerald and Brean Capital....
BC Week In Review | Aug 17, 2015
Clinical News

AXS-02: Phase III started

Axsome began the double-blind, placebo-controlled, international Phase III CREATE-1 to evaluate once-weekly oral AXS-02 for 6 weeks in 190 patients with pain associated with CRPS. AXS-02 has Fast Track designation in the U.S. and Orphan...
BC Week In Review | Apr 13, 2015
Clinical News

AXS-02 regulatory update

FDA granted Fast Track designation to Axsome’s AXS-02 to treat complex regional pain syndrome (CRPS). The oral, non-opioid candidate is in clinical testing for CRPS, for which it has Orphan Drug designation in the U.S....
BC Extra | Mar 6, 2015
Company News

Axsome's AXS-02 gets Fast Track for complex regional pain

FDA granted Fast Track designation to AXS-02 from Axsome Therapeutics Inc. (New York, N.Y.) to treat complex regional pain syndrome (CRPS). The oral, non-opioid candidate has Orphan designation in the U.S. and EU for CRPS....
Items per page:
1 - 8 of 8